This is all to say that my experience with Civilization 7 during the review period was mostly long play sessions of obsession ...

The FDA recently accepted for review the Company’s supplemental New Drug Application (sNDA) requesting modification of liver monitoring for FILSPARI in IgAN and assigned a PDUFA target action ...

Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for ...

The FDA recently accepted for review the Company's supplemental New Drug Application (sNDA) requesting modification of liver ... interactions with the FDA regarding a potential regulatory pathway for ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer: Thousand Oaks, California Monday, January 20 ...

Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

By modulating sGC via a heme-independent pathway, the investigational sGC activator now represents ... In Cardiovascular, Bayer submitted a supplemental new drug application (sNDA) to the U.S. Food ...

Welireg's sNDA for advanced PPGL treatment is under FDA priority review, potentially becoming the first U.S. therapy for this condition. The LITESPARK-015 trial supports the sNDA with ORR and DOR data ...